Collaboration with Mabion S.A

📢 The start of the collaboration with Mabion is the next important step in the execution of ODDIFACT's strategy. The reactivation of the MabionCD20 project opens a new pathway toward commercialization of the product in rare disease indications, with the potential to improve patients’ quality of life in areas of high unmet medical need.

✅ By combining Mabion’s in-house expertise and experience in biologics with ODDIFACT’s AI-driven approach, both companies are confident in the success of this and future CD20-related projects.

Mabion-is-back-–-reactivation-of-the-MabionCD20-project-opens-the-way-to-commercializing-t.

Download • 154KB